BMS announces first presentation of results for Opdivo + Yervoy in hepatocellular carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Bristol-Myers Squibb Co. announced first results from the Opdivo (nivolumab) plus Yervoy (ipilimumab) cohort of the phase I/II CheckMate-040 study, evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login